Evaluation of the Efficacy and Safety of Hyaluronic Acid Injection in Labia Majora for Volume Restoration
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 72
- 试验地点
- 14
- 主要终点
- Proportion of patients having an improvement on the Global Aesthetic Improvement Scale (GAIS)
研究概览
简要总结
DESIRIAL® PLUS is a CE-marketed hyaluronic acid (since 2011) whose registered indications are moderate hypotrophy, severe hypotrophy or atrophy of the vulvar Labia Majora by subcutaneous injections. The aim is to restore volume, rehydrate and add tone and tension to connective tissue areas by filling.
In this study, 71 female subjects above or equal to 18 years old at inclusion, who have moderate hypotrophy or severe hypotrophy or atrophy of the vulvar Labia Majora (according to investigator's judgement), who have given her informed consent and meet all the eligibility criteria, will be enrolled. Subjects will come to a total of 6 visits over a period of 12 months. An optional screening visit may be done before injection (additional visit). Proportion of patients having an improved perception of aesthetics (GAIS score after mirror self-examination) after baseline injection will be assessed. Global Aesthetic Improvement, Sexual function, subject's satisfaction, subject's symptoms, pain at injection and safety will be also assessed.
详细描述
ESOLANE is a prospective multicenter post-marketing study of a class III medical device. This uncontrolled open-label study investigates the efficacy and safety of DESIRIAL® PLUS in volume restoration of Labia Majora. The study duration is 12 months with an optional screening visit (V0) up to 14 days before injection, the baseline visit (injection of DESIRIAL®PLUS, V1) and 5 follow-up visits after 4, 12, 24, 36 and 52 weeks (V2 to V6). At 4 weeks (V2) an optional touch-up may be done (if needed). It is envisaged to enrol 71 female patients with the wish for volume restoration in France to obtain at least 60 evaluable patients, which will be monitored over 1 year after baseline injection of DESIRIAL® PLUS.
The primary endpoint is defined as the proportion of patients having an improved perception of aesthetics (GAIS score after mirror self-examination) at 12 weeks after baseline injection of DESIRIAL® PLUS, which may be touched-up once after 4 weeks (V2).
Global Aesthetic Improvement (evaluated by the patient and the doctor), Sexual function, subject's satisfaction, subject's symptoms & pain, will be measured at all time-point with a Global Aesthetic Improvement Scale (GAIS), Female Sexual Function Index (FSFI), patient's satisfaction questionnaire (PSQ) and a Numerical Rating Scale (NRS) respectively. Safety will be also assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Women with the following conditions :
- •≥ 18 years of age at inclusion
- •Moderate hypotrophy, severe hypotrophy or atrophy of the vulvar Labia Majora, according to the investigator's judgement
- •Expressed the wish for volume restoration of the Labia Majora
- •Able to understand and sign the informed consent for study enrolment
- •Subject affiliated to a health social security system
- •Non-inclusion Criteria
- •Pregnancy
- •Breast feeding
- •Known tendency to develop hypertrophic scars or keloid scars
- •Participating at the same time in another clinical trial
- •Deprived of their freedom by administrative or legal decision or under guardianship
- •Linked to inflammatory or immune status:
- •Known hypersensitivity
- •to one of DESIRIAL® PLUS's components (hyaluronic acid, mannitol)
- •to the antiseptic solution that is planned to be used in this study
- •to amide local anesthetics or to one of the components of the anesthesia product that is planned to be used in this study
- •Presence of clinical signs of inflammatory in or close to the area of interest or treatment for these affections
- •History of or ongoing auto-immune disease
- •Suffering from hemostatic disorder
- •Linked to infection:
- •Presence of bacterial, fungal or viral infection in or close to the area of interest or treatment for these affections
- •History of streptococcal illness (such as recurrent sore throat or acute articular rheumatism)
- •Recurrent genital herpes (several times a year)
- •Linked to neoplasia:
- •History of cancer in areas close to the injection site (external urogenital, anal or vaginal)
- •Actual cancer or presence of pre-cancerous cells (e.g. vaginal dysplasia)
- •Linked to previous or ongoing treatments:
- •Under treatment with aspirin, anticoagulant, platelets aggregation inhibiting drugs, NSAIDs and Vitamin C or treated within 1 week prior to inclusion
- •Under local hyaluronic acid-like hydrating treatment within 4 weeks prior to inclusion
- •History of hyaluronic acid injection of >14 ml in any part of the body within the last year
- •History of correction with DESIRIAL® range or other resorbable implants with similar indication within 1 year prior to inclusion
- •History of correction with permanent implants including fat graft or semi-permanent in the area of injection
- •Surgical history on Labia Minora within one year prior inclusion
- •Surgical history on Labia Majora
排除标准
- 未提供
结局指标
主要结局
Proportion of patients having an improvement on the Global Aesthetic Improvement Scale (GAIS)
时间窗: 12 weeks
Proportion of patients having an improvement on the GAIS, evaluated by the patient (after mirror self-examination), 12 weeks after baseline injection. 5 possible grades: 1) Very much improved, 2) much improved, 3) improved, 4) no change, 5) worse
次要结局
- Sexual function assessment(4 weeks, 12 weeks, 24 weeks, 36 weeks, 52 weeks)
- Patient's satisfaction: questionnaire (PSQ)(4 weeks, 12 weeks, 24 weeks, 36 weeks, 52 weeks)
- Patient aesthetic evolution(4 weeks, 12 weeks, 24 weeks, 36 weeks, 52 weeks)
- Patient's assessment of pain related to the injection(Baseline (injection))
- Patient self-assessed aesthetic evolution(4 weeks, 24 weeks, 36 weeks, 52 weeks)
- Assessment of patient's symptoms(4 weeks, 12 weeks, 24 weeks, 36 weeks, 52 weeks)
- Report of adverses effects(Up to 52 weeks)